Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydroVax-001B WNV Vaccine in Healthy Adults
NCT06745921Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HydroVax-001B WNV in West Nile Virus Infection (WNV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events at Day 29, Serious Adverse Events at 13 months and 1 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
HydroVax-001B WNV
03
Conditions
West Nile Virus Infection (WNV)
Beyond the preview
Go deeper on NCT06745921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745921.